Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar. Closed at $1.60, 47% below $3.03, its close on the day of its Oct 13 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$124,000Cash on Hand
0.6mo Cash Runway
Follow TCRT by emailGet an email when TCRT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TCRT, unsubscribe in one click. Privacy
📣 What TCRT Says Is Next
in 2028 · “We believe this transaction and the concurrent private placement provide a strong financial foundation for us to advance an exciting pipeline and offer our stockholders a compelling opportunity to realize value, with proof-of-concept data for VLR199 expected in 2028.” Management & Organization: In conjunction with the transaction, Peter Harwin, Founding Partner of Fairmount, will join the Board of Directors for Alaunos.”
Company press release, Oct 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Financing Alaunos registered for resale up to 382,090,789 shares of common stock held by selling stockholders, mostly issuable on conversion of Series B and C preferred stock issued in the Velaris asset acquisition and an October 2026 private placement. The company will not receive proceeds. Form S-3 · SEC filing
Oct 23, 2026 ·
Listing Nasdaq closed its stockholders' equity deficiency matter for Alaunos after confirming the company regained compliance following its October 14, 2026 private placement. The November 10, 2026 Panel hearing was cancelled and the stock stays listed on The Nasdaq Capital Market. Form 8-K · SEC filing
Oct 21, 2026 ·
Listing Nasdaq hearing scheduled for November 10, 2026, after a delisting notice for stockholders' equity below $2.5 million. The company closed its Velaris merger and a $350.0 million private placement on October 14, 2026. Form 8-K · SEC filing
Oct 13, 2026 ·
Deal Alaunos completed its acquisition of Velaris Therapeutics in a stock-for-stock merger, issuing 105,286 Series B and 33,054 Series C non-voting convertible preferred shares to Velaris holders. Form 8-K · SEC filing · Press release
Oct 9, 2026 ·
Listing Received a Nasdaq delisting notice on Oct 5, 2026 for not meeting the $2,500,000 minimum stockholders' equity rule, and plans to request a hearing before the Nasdaq Hearings Panel. It is working with a financial advisor on strategic alternatives, with no assurance of compliance. Form 8-K · SEC filing
Sep 22, 2026 ·
Financing Alaunos Therapeutics agreed to sell 380,469 common shares and pre-funded warrants for 386,654 shares at $1.46 per share, with net proceeds of about $915,400.50 after placement agent fees and expenses, closing September 21, 2026. Form 8-K · SEC filing · Press release
Sep 21, 2026 ·
Financing Alaunos Therapeutics is offering 380,469 common shares at $1.46 per share and pre-funded warrants at $1.459 each, for gross proceeds of up to about $1.1 million through placement agent Dawson James Securities on a best-efforts basis. Form 424B3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2025 · N/A · Results Expected · Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs Registry primary completion date, not a results date
Oct 2020 · Phase 1 · Results Expected · A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 Registry primary completion date, not a results date
Aug 2019 · Phase 1 · Results Expected · A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma Registry primary completion date, not a results date
Apr 2019 · Phase 1 · Results Expected · Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Registry primary completion date, not a results date
Sep 2014 · Phase 1/2 · Results Expected · Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma Registry primary completion date, not a results date
Jan 2013 · Phase 1 · Results Expected · Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not TCRT's own candidates): Carboplatin, Etoposide, Aldesleukin, Cemiplimab-Rwlc, Capecitabine, Carmustine, Cytarabine, Nivolumab, Erlotinib Hydrochloride, Interleukin-2.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
TCRT holds $124,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $665,500/quarter from operations,
an estimated runway of 0.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:75 · High
Cash runway 1 months +40
Shelf registration (S-3, Aug 2025) +10
Going-concern doubt in the latest 10-Q +15These conditions initially raised substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Share count +89% in a year +20
Raised after last reported balance sheet (Oct 2026) -10
Share count 4,208,359 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full TCRT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TCRT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.